<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arnaud Capron</style></author><author><style face="normal" font="default" size="100%">Michel Mourad</style></author><author><style face="normal" font="default" size="100%">Martine De Meyer</style></author><author><style face="normal" font="default" size="100%">Luc De Pauw</style></author><author><style face="normal" font="default" size="100%">Eddour, Djamila Chaib</style></author><author><style face="normal" font="default" size="100%">Dominique Latinne</style></author><author><style face="normal" font="default" size="100%">Laure Elens</style></author><author><style face="normal" font="default" size="100%">Haufroid, Vincent</style></author><author><style face="normal" font="default" size="100%">Wallemacq, Pierre</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacogenomics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">ATP Binding Cassette Transporter, Subfamily B, Member 1</style></keyword><keyword><style  face="normal" font="default" size="100%">Blood Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical Laboratory Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytochrome P-450 CYP3A</style></keyword><keyword><style  face="normal" font="default" size="100%">Exons</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunosuppressive Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Introns</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Research</style></keyword><keyword><style  face="normal" font="default" size="100%">Tacrolimus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 May</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;AIMS: &lt;/b&gt;This prospective study investigated the effect of genetic polymorphisms in a biotransformation enzyme (CYP3A5) and a transporter protein (ABCB1) on tacrolimus (Tac) whole blood concentrations in renal transplantation, and more specifically on peripheral blood mononuclear cell (PBMC) drug concentrations, after renal transplantation.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;MATERIALS &amp;amp; METHODS: &lt;/b&gt;A total of 96 renal transplant recipients were genotyped for the exon 11 (1199G&amp;gt;A), 21 (3435C&amp;gt;T) and 26 (2677G&amp;gt;T/A) polymorphisms in the ABCB1 gene and for the intron 3 polymorphism in the CYP3A5 gene. Tac blood and PBMC concentrations were determined at day 7 after transplantation and at steady state, and then compared with recipient genotypes.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS &amp;amp; CONCLUSION: &lt;/b&gt;The ABCB1 1199G&amp;gt;A, 3435C&amp;gt;T and 2677G&amp;gt;T/A SNPs, appeared to reduce the activity of P-glycoprotein towards Tac, increasing Tac PBMC concentrations. The impact of ABCB1 genetic polymorphisms on Tac blood concentrations was negligible. As increased Tac intracellular concentrations might in turn enhance immunosuppressive status and prevention or rejection, ABCB1 recipient genotyping might be useful to better individualize the Tac immunosuppressive therapy in renal transplantation.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record></records></xml>